Ganoderic acid D (GD) is the major active triterpenoid in Ganoderma lucidum, a medicinal fungus used daily. However, the metabolic fate of GD remains unknown. To know whether GD is extensively metabolized, we first investigated the metabolism of GD in vitro and in vivo. The metabolic profiles of the bile samples obtained from rats in vivo were almost the same as those obtained in vitro. Using ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry, a total of 25 metabolites were identified from the bile sample. Few metabolites were found in the urine samples. These results indicated that biliary rather than renal clearance was the major route of excretion. The major metabolites were identified by comparison with the standard reference compounds. Metabolites at low concentrations were identified by interpreting the mass spectra. Both phase I and phase II metabolites were observed. The metabolic transformation included reduction, monohydroxylation, dihydroxylation, trihydroxylation, oxidation, desaturation, sulfation, and glucuronidation. The main metabolic soft spots in the chemical structure of GD were the 3-carbonyl group, angular methyl groups, the 7-hydroxy group, and the 26-carboxylic acid moiety. Overall, this study gives us an insight into the metabolism of GD, an active oxygenated tetracyclic triterpenoid.
Introduction
Ganoderic acid D (GD), a highly oxygenated tetracyclic triterpenoid, is the main active component of Ganoderma lucidum, which has been widely used as a dietary supplement or prescribed in the clinic in eastern countries to cure many types of diseases (Shiao, 2003; Paterson, 2006; Zhou et al., 2006; Boh et al., 2007; Olaku and White, 2011) . Previous studies from our group revealed that 48 h of GD treatment inhibited the proliferation of HeLa human cervical carcinoma cells with an IC 50 value of 17.3 Ϯ 0.3 M. Flow cytometric analysis and DNA fragmentation analysis indicated that GD induced G 2 /M cell cycle arrest and apoptosis. The cytotoxic effect of GD was associated with regulated expression of 21 proteins (Yue et al., 2008) .
At present, the metabolic fate of GD remains unknown. To investigate the metabolism of GD and get an insight into the metabolic pathways of the natural oxygenated tetracyclic triterpenoids (Guo et al., 2012) , as one part of our research, we performed an in vivo and in vitro metabolite identification study for GD in rat using ultra-performance liquid chromatography (UPLC)/quadrupole time-of-flight (Q-TOF) mass spectrometry (MS) coupled with a metabolic identification-specific software provided from the instrument vendor. This UPLC/Q-TOF MS coupled with a chemical intelligent software workflow has proven to be a fast and effective approach for identification of metabolites of xenobiotics in recent years (Bateman et al., 2007; Zhang et al., 2009; Ibáñez et al., 2011) .
In metabolism studies, it is very important to identify and characterize the chemical structure of metabolites (Levsen et al., 2005; Holčapek et al., 2008) . In the present study, the main metabolites were easily identified by comparing fragmentation ions obtained from MS and chromatographic behaviors of the authentic standards. However, the assignment of the minor unknown metabolites was a challenge because of the complication of the mass fragmentation patterns in the tetracyclic skeleton of GD. Fortunately, we had systematically studied the fragmentation pathways of oxygenated tetracyclic triterpenoids (Cheng et al., 2011) and found that mass cleavages of the ring skeleton were very characteristic and related to the chemical structure (Fig. 1) . These fragmentation patterns can be used as a critical clue during the study of GD metabolism. In the end, 25 metabolites were identified from rat bile, and the metabolic pathways of GD are proposed. To the best of our knowledge, this is the first report ever on the full metabolite profiles of GD, a highly oxygenated tetracyclic triterpenoid. In addition, this study also shows the effectiveness of highresolution mass spectrometry in metabolic studies of complicated drug, especially natural product-related drugs.
Materials and Methods
Chemicals and Reagents. Ganoderic acid D and the reference compounds (ganoderic acid B and ganoderic acid E) were isolated from the fruiting bodies of G. lucidum. Their chemical structures were unambiguously identified by the comparison of their NMR and MS spectra data with those reported in the literature (Kubota et al., 1982; Kikuchi et al., 1985; Kohda et al., 1985; Cheng et al., 2010) . Their purities were more than 98% as determined by highperformance/UV analysis. Acetonitrile, methanol, and formic acid were of high-performance liquid chromatography-grade (Honeywell Burdick & Jackson, Muskegon, MI). Ultra-pure water was prepared using a Milli-Q water purification system (Millipore Corporation, Billerica, MA). Pooled rat liver microsomes were purchased from In Vitro Technologies (Baltimore, MD). 1,1,1-Tris(hydroxymethyl)aminomethane (50 -100 mM) and the NADPH-regenerating system were purchased from Sigma-Aldrich (St. Louis, MO). All other reagents were analytical reagent grade (Sinopharm Chemical Reagent Co. Ltd., Shanghai, China).
Animals. Male Sprague-Dawley rats (180 -220 g) were obtained from the Laboratory Animal Center of Shanghai Institute of Materia Medica (Shanghai, China). They were kept in an environmentally controlled animal room (20 Ϯ 2°C, 60 Ϯ 5% humidity, and 12-h dark/light cycle) for 7 days before the experiments were started. Rats were fed standard laboratory food with water ad libitum and fasted overnight before the test. The animal facilities and protocols were approved by the Animal Care and Use Committee of Shanghai Institute of Materia Medica.
Drug Administration and Sample Preparation. Pure GD (14 mg) was dissolved in 1 ml of acetone. Stearic acid (28 mg) and soybean lecithin (54 mg) were dissolved in 3 ml of CH 2 Cl 2 . The two solutions were mixed and evaporated at 40°C to dryness in vacuum. The residue was dissolved in 1% Tween 80 (6 ml) and sonicated for 2 h. The homogeneous solution was given to rats orally at 10 mg/kg.
Under light anesthesia, bile fistulas in three rats were cannulated with polyethylene 5 tubing for bile collection. The bile was collected for 12 h after dosing. The rats were allowed to recover from anesthesia before the administration. Blank bile was collected before dosing. HCl solution (2%) was added to the bile samples (300 l) until pH was 2. The solution was extracted twice, each time with 600 l of ethyl acetate. The combined extracted solution was blown to dryness with a nitrogen stream. The residue was dissolved with 200 l of methanol and filtered through a 0.22-m microporous membrane before injection.
Rats were held in metabolism cages, and urine samples (including the blank) were collected for 24 h. The pH of the urine (15 ml) was adjusted to 2 with HCl solution (2%) before it was extracted with ethyl acetate (two extractions of 30 ml). The combined extracted solution was blown to dryness with a nitrogen stream. The residue was dissolved with 200 l of methanol and filtered through a 0.22-m microporous membrane before injection.
Blood was collected from the angular vein at 0.25, 0.5, 1, and 2 h. A sample from each time point was first centrifuged at 4000 rpm for 10 min and then 400 l of the plasma was taken for further sample preparation. Each plasma sample was treated with 200 l of 2% HCl and 1.2 ml of acetonitrile to adjust the pH and to precipitate the protein. After centrifugation at 4000 rpm for 5 min, the supernatant was blown to dryness with a nitrogen stream. The residue was dissolved with 200 l of methanol and filtered through a 0.22-m microporous membrane before injection.
In Vitro Metabolism Studies. The rat liver microsomes were carefully thawed on ice before the experiment. GD (100 M) was mixed with the microsomes (the concentrations of microsomal protein were 1.0 mg/ml) in 100 mM 1,1,1-tris(hydroxymethyl)aminomethane buffer (pH 7.4). The total incubation volume was 1 ml. After 3 min of preincubation at 37°C, the incubation reaction was initiated by the addition of NADPH (3.0 mM) and UDP-glucuronic acid (3.0 mM). After a 1-h incubation, the reactions were terminated with 1 ml of ice-cold acetonitrile. The mixture was centrifuged at 12,000 rpm for 15 min, and 10 l of the supernatant was directly injected for UPLC/Q-TOF MS experiments. Control samples containing no NADPH or substrates were prepared. Each of the incubations was performed in duplicate.
LC-MS Methodology. Chromatographic separation was achieved using an Acquity UPLC system (Waters, Milford, MA) on an Acquity UPLC HSS T3 column (1.8-m, 2.1 ϫ 100 mm; Waters). The mobile phase was a mixture of 0.05% formic acid in water (A) and acetonitrile (B). The gradient elution started from 98% A to 40% A linear in 16 min, then reached 0% A linear at 17 min, and was equilibrated at 98% A for 3 min. The column temperature was set at 45°C, and the flow rate was 0.6 ml/min. The mass spectrometry detection was performed using a Waters Xevo G2 Q-TOF high-resolution mass spectrometer operated in negative ion electrospray mode. Nitrogen and argon were used as desolvation gas and collision gas, respectively. Data acquisition was from 50 to 1200 Da with source temperature set at 120°C, desolvation temperature set at 550°C, and cone voltage set at 16 V. A centroid data collection mode was used. The lock spray standard was 400 ng/ml leucine enkephalin (m/z 554.2615 in negative ion electrospray mode) solution infused at 5 l/min. MS E data acquisition was used. The collision energy was 2 V for the low-collision energy scan and 30 to 70 V for the high-collision energy scan. The mass spectrometer and UPLC system were controlled by MassLynx 4.1 software (Waters). Data processing was by MetaboLynx XS 2.0 (Waters). As a result of the MS E data acquisition, for each sample, both precursor ion and fragment ion information were obtained from a single liquid chromatograph injection. During data processing, MetaboLynx XS would first apply an exact mass defect filter (MDF) and then compare all peaks (still remaining after applying the MDF) from the dose sample with those from the control sample. The ⌬ mass (⌬m) used for the mass defect filter is 50 mDa. Potential metabolites were reported from the MetaboLynx browser, which could be studied further for structural elucidation by a simple review of the fragment ions obtained from the same injection.
Results
Characterization of GD and the Metabolites in Rat Bile. Thirtytwo potential metabolites were listed from the MetaboLynx Browser after the UPLC/Q-TOF MS E data acquisition and data processing by MetaboLynx XS 2.0 (Supplemental Fig. 1 ). As a result, the general metabolic patterns were tentatively assigned (Supplemental Fig. 2 ). After further review of the fragment ion information, a total of 25 metabolites of GD were identified from the rat bile sample (shown in Fig. 2 ). The structures of metabolites were confirmed by comparison of chromatographic retention times and mass spectra with available reference standards or by a study of the characterized mass spectral fragmentation patterns. Parent compound M0. The retention time of the parent compound GD was 11.3 min. The high-collision energy mass spectrum of GD is shown in Fig. 1 . In negative ion mode, a series of important fragment ions were obtained. The proposed fragmentation pathways are depicted in Fig. 1 Ϫ , calculated m/z 249.149) generated from ring D cleavage and ring C cleavage, respectively, were 2 Da heavier than the parent compound, whereas the ion at m/z 149.060 resulting from ring C and ring A cleavages remained the same. These results indicated that the modification occurred on the 3-carbonyl group of ring A. Therefore, M1 was identified as 3,7-dihydroxy-11,15,23-trioxolanost-8-en-26-oic acid. This conclusion was confirmed by comparing the retention time and high-collision energy mass spectrum with those of the authentic standard (ganoderic acid B). M1 and M0 could also be detected from the bile sample at 252 nm using a liquid chromatography-diode array detector instrument. (Cheng et al., 2011) . Therefore, M2 was identified as 3,7,11,15,23-pentaoxolanost-8-en-26-oic acid. The structure of M2 was confirmed by comparison with the authentic standard (ganoderic acid E).
Metabolites M9 and M10. Both metabolites M9 and M10 (t R ϭ 8.9 and 8.7 min) exhibited a [M Ϫ H] Ϫ ion at m/z 529.281, 16 Da heavier than the parent compound. The high-collision energy mass spectra of M9 and M10 were the same, suggesting that they were a pair of isomers. As shown in Fig. 5 Ϫ , calculated m/z 233.118) were generated from the ring D cleavage and ring C cleavage, respectively, followed by the loss of a molecule of HCHO. The key ion at m/z 149.062 was generated from ring C and ring A cleavages. These data indicated that the hydroxylation occurred on an angular methyl group of ring A (position 28 or 29). Therefore, M9 and M10 were tentatively characterized as 7,28(or 29)-dihydroxy-3,11,15,23-tetraoxolanost-8-en-26-oic Ϫ (m/z 96.960) was also observed. In the chemical structure of GD derivatives, the 7-hydroxy-15-oxo groups are the crucial features for the cleavage of ring C (Cheng et al., 2011) . The existence of the ring C cleavage suggested that the 7-OH remained intact, and the sulfation occurred on 3-OH. A reduction reaction first occurred on the 3-carbonyl group, and then the 3-hydroxy group was conjugated with sulfuric acid. Therefore, M23 was tentatively identified as 7-hydroxy-11,15,23-trioxo-3-sulfooxylanost-8-en-26-oic acid.
Detailed interpretation of all other metabolites can be found in the supplemental data.
Characterization of the Metabolites in Rat Plasma and Urine. In the UPLC/Q-TOF MS chromatograms of the plasma and urine samples, the main metabolite M1 (ganoderic acid B) and the parent drug (ganoderic acid D) could be detected in plasma (Supplemental Figs. 3 and 4). However, no metabolite or the parent compound could be detected in the urine sample (Supplemental Figs. 5 and 6) .
Characterization of the Metabolites of GD In Vitro in Rat Liver Microsomes. The metabolites detected in the rat liver microsomes incubations were similar to those found in the bile samples. The metabolite M1 formed by the reduction was the most abundant metabolite in vitro. The monohydroxylated metabolites in the incubations included M4, M5, M8, M9, and M10. The dihydroxylated metabolites detected in vitro included M15 and M20. The metabolite M13 formed by the hydroxylation and reduction was observed. The phase II metabolites M24 and M25 formed by the glucuronidation reaction were also identified in the in vitro samples.
Discussion

Metabolism of GD in Rat.
In the present study, we first investigated the metabolites of GD from rat bile, plasma, and urine. By using the UPLC/Q-TOF MS scan coupled with MetaboLynx XS screening, 25 metabolites were tentatively identified from the bile and 1 metabolite from the plasma. There was no metabolite or parent drug found in the urine. These results indicated that hepatocyte metabolism was the major route of clearance for this compound. This result was in agreement with the theory that the drugs and metabolites whose molecular mass ranged from 500 to 600 Da preferentially excreted into the bile (the molecular mass of GD was 514 Da) (Ghibellini et al., 2006) . Because the volume of the blood sample was low, only ganoderic acid B and the parent compound (GD) were found in the plasma sample.
The metabolic profiles of the in vivo samples were in agreement with those of the in vitro samples. All phase I and phase II metabolites found in vitro were also observed in the bile samples. Because the analyte concentrations of the bile samples were higher, more low- 
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at ASPET Journals on November 6, 2017 dmd.aspetjournals.org level metabolites, such as the monohydroxylated metabolite (M6), dihydroxylated metabolite (M17), and trihydroxylated metabolite (M21), were found in the in vivo samples. Both the in vivo and in vitro experiments indicated that liver played an important role in the clearance of GD in rat.
Proposed metabolic pathways of GD are depicted in Fig. 4 . Both phase I and phase II metabolites were observed. The formation of the phase I metabolites in rats involved reduction (M1), hydroxylation (M4 -M10 and M15-M22), desaturation (M3), and oxidation (M2). Among phase I metabolites, the product of reduction (ganoderic acid B) was the most abundant metabolite. This compound was a natural compound separated from G. lucidum. Hydroxylation products were also extensively observed. This type of reaction involved the addition of one, two, or even three hydroxyl groups to the parent drug. In some metabolites, two metabolic transformations occurred simultaneously. For example, metabolite M11 was formed by the desaturation reaction followed by a hydroxylation reaction. The phase II biotransformation observed included sulfation and glucuronidation. The phase II metabolite M23 was formed by a reduction reaction followed by a sulfation reaction. M24 and M25 were formed by the conjugation between the parent compound and glucuronic acid. The glucuronidation metabolites of metabolite M1 (ganoderic acid B) were also detected by the low-collision energy scans and predicted by the MetaboLynx software ( Supplemental Fig. 2) ; however, the signals of the corresponding high-collision energy mass spectra were too weak to give a reasonable chemical structure.
The chemical structure of GD is composed of a highly oxygenated tetracyclic ring skeleton and an acidic side chain (Fig. 1) . The 3-carbonyl group is the most vulnerable metabolic soft spot. It can be quickly transformed to a hydroxyl group by a reduction reaction. However, this type of reaction was not observed on the other carbonyl group in the chemical structure of GD. The angular methyl groups (on positions 19, 28, 29, and 30) easily undergo hydroxylation reactions. Of interest, the hydroxylation reaction has not been observed to occur on the CϪH bond of the ring (except C-2). For example, the 12-OH derivatives of GD are extensively found from the extraction of G. lucidum (Cheng et al., 2011) ; however, this type of compounds has not been detected in the biosamples of GD. This phenomenon may be caused by the spatial structure of GD. The angular methyl groups are on the outside of the chemical structure and are easily exposed to the large-size enzyme that mediates the hydroxylation reactions. Because of the high steric hindrance, the CϪH bonds on the ring cannot be associated with the active site of the enzyme and do not undergo the hydroxylation reaction. The 7-hydroxyl group can be oxidized to a carbonyl group or conjugated to the glucuronic acid. The C16ϪC17 can go through a desaturation reaction to form the 276, 451.287, 301.181, 247.133, 193.036, 175.025, 113.024, 85.029 
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at ASPET Journals on November 6, 2017 dmd.aspetjournals.org ␣,␤-unsaturated carbonyl group. The 26-carboxylic acid group can form O-glucuronide. The ␣ or ␤ position of the carboxylic acid group can also undergo hydroxylation reactions. In short, the main metabolic soft spots of the chemical structure of GD are the 3-carbonyl group, angular methyl groups, the 7-hydroxyl group, and the 26-carboxylic acid moiety. Interpretation of the Mass Spectra and Importance of HighResolution Mass Spectrometry. Characterization of the metabolites of GD was a challenge because of the complication of the fragment ions generated by the cleavages of the ring skeletons. Previously, we had systematically studied the fragmentation pathways of oxygenated tetracyclic triterpenoids. We found that the fragmentation of the triterpenoid acids was rather characteristic in negative ion mode. After the prominent loss of H 2 O and CO 2 , cleavages took place on the A, B, C, and D rings. The cleavage site was highly dependent on the positions of the carbonyl groups and hydroxyl groups in the tetracyclic skeleton (Cheng et al., 2011) . GD is a 7-hydroxy-11,15-dioxo derivative. The main fragmentation pathways of this type of compound are the cleavages of ring C and ring D. Different substitutions on the chemical structure will result in different m/z of the fragment ions. These decomposition features are extremely useful in distinguishing the isomers generated by the metabolic transformation.
The fragment ions generated by Q-TOF mass spectrometry are abundant. The spectra generated can be divided into two areas as High-resolution mass spectrometry is very important in metabolic studies. The Q-TOF instrument offers high sensitivity in the full-scan MS and MS E modes of operation. Of more importance, it can measure the exact mass of precursor ion and fragment ions and provides elemental composition of the corresponding ions. There are some who think that low-resolution mass spectrometry instruments, such as ion trap, triple quadrupole, and quadrupole-ion trap, are sufficient for the identification of metabolites. However, the correct interpretation of low-resolution mass spectra becomes increasingly difficult when we are confronted with complicated chemical structures, especially those for natural drugs.
The present study shows the importance of high-resolution mass spectrometry and proves its value. For example, the ⌬m values for the loss of two methyl radicals and a molecule of HCHO are both 30 Da. In low-resolution mass spectrometry, we cannot distinguish the two species from one another. In high-resolution mass spectrometry, the exact mass of two methyl radicals is 30.047, whereas the exact mass of HCHO is 30.011 and the two species can be easily distinguished. In Fig. 5 , the ⌬m between the two ions of m/z at 511.271 and 481.260 is 30.011. This result suggests that a molecule of HCHO is lost from the fragment ion at m/z 511.271 and indicates the existence of a hydroxymethyl group connected to a quaternary carbon. Without the information provided by high-resolution mass spectrometry, we might make a mistake and consider ⌬m ϭ 30 to be the loss of two methyl radicals, which would lead to false identification of a 7,11-dioxo derivative.
When identification of metabolites for biological samples is performed, the most difficult challenge is the interference of endogenous compounds from the biological matrix. This is where the exact mass capability of the time-of-flight mass spectrometer plays a crucial role. During data processing, MetaboLynx XS will apply a mass defect filter to the raw data set so that only the ingredients with mass defects that fit into the parameter requirement will be included for further data mining; all others will be excluded. The mass defect parameters are set on the basis of the parent drug mass defect plus all mass detects from the fragments that potentially could become subparent metabolites. Supplemental Fig. 1 shows the effects of the exact mass defect filter. Many irrelevant peaks are excluded.
The software will further process the MDF filtered raw data files to compare all peaks from the dose sample with those from the control sample. Potential metabolites are displayed in the MetaboLynx browser (Supplemental Fig. 2 ) and can be further studied for structural elucidation. Most of the metabolites in the list can be characterized; only the structures of several minor metabolites cannot be assigned because of the weak signal of the fragment ions.
In conclusion, the present study reports for the first time on the comprehensive metabolic profile of GD in vivo and in vitro. The results reveal that hepatocyte metabolism is the major route of clearance for GD. By using a UPLC/Q-TOF MS/MetaboLynx XS workflow, a total of 25 metabolites were identified from the rat bile samples. GD could undergo extensive phase I and II metabolism in rat before it is excreted into bile. The phase I metabolism included reduction, hydroxylation, oxidation, and desaturation. The reduction product (ganoderic acid B), which is also a naturally occurring compound, was the main metabolite. Hydroxylation metabolites, including monohydroxylation products, dihydroxylation products, and trihydroxylation products, were extensively found. The phase II metabolism included sulfation and glucuronide conjugation. The main metabolic soft spots of the chemical structure of GD were the 3-carbonyl group, angular methyl groups, the 7-hydroxyl group, and the 26-carboxylic acid moiety. This study has increased our knowledge of the metabolic pathways of an oxygenated tetracyclic lanostane triterpenoid. These results lay a solid foundation for further metabolic and clinical studies of ganoderic acids.
